Correlation between hospitalized patients’ demographics, symptoms, comorbidities, and COVID-19 pandemic in Bahia, Brazil

Macedo, Márcio C. F.; Pinheiro, Isabelle Matos; Carvalho, Caio J. L.; Fraga, H; Araujo, Isaac P. C.; Montes, Simone S.; Araujo, Otávio A. C.; Alves, Leonardo Santos de Brito; Saba, Hugo; Araújo, Márcio Luís Valença; Queiroz, Ivonete T. L.; Sampaio, Romilson Lopes; Souza, Márcia São Pedro Leal; Silva, Ana Claudia F. N. da; Souza, Antonio Carlos Santana de

doi:10.1371/journal.pone.0243966

Cited by 23 publications

(23 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current study, we found the main predictors of mortality to be male sex, advanced age, cardiovascular disease, diabetes mellitus, chronic respiratory disease, systemic arterial hypertension, obesity and chronic kidney disease. These data corroborate previous studies that indicate the presence of previous comorbidities as an important factor for worsening of the condition [ 27 , 28 , 30 , 32 , 38 , 39 ]. In a study conducted in Pernambuco, Brazil, the presence of cardiovascular diseases, for example, accelerated mortality from COVID-19 by 4 days when compared to individuals without comorbidities [ 40 ].…”

Section: Discussionsupporting

confidence: 92%

“…Among survivors, the most frequent symptoms were fever, cough and headache, while respiratory symptoms were more frequent in individuals who died. Other studies have found a significant association between shortness of breath and death risk [ 27 , 32 ] (Macedo, 2020; Soares, 2020). In the respiratory system, angiotensin-converting enzyme 2 expression facilitates the entry of SARS-CoV-2, which mainly infects ciliated cells and type II alveolar cells [ 33 ].…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

COVID-19 in Brazil: spatial risk, social vulnerability, human development, clinical manifestations and predictors of mortality – a retrospective study with data from 59 695 individuals

et al. 2021

View full text Add to dashboard Cite

Brazil ranks second in the number of confirmed cases of COVID-19 worldwide. In spite of this, coping measures differ throughout the national territory, as does the disease's impact on the population. This cross-sectional observational study, with 59 695 cases of COVID-19 registered in the state of Alagoas between March and August 2020, analysed clinical-epidemiological variables, incidence rate, mortality rate, case fatality rate (CFR) and the social indicators municipal human development index (MHDI) and social vulnerability index (SVI). Moran statistics and regression models were applied. Logistic regression analysis was applied to determine the predictors of death. The incidence rate was 1788.7/100 000 inhabitants; mortality rate was 48.0/100 000 and CFR was 2.7%. The highest incidence rates were observed in municipalities with better human development (overall MHDI (I = 0.1668; p = 0.002), education MHDI (I = 0.1649; p = 0.002) and income MHDI (I = 0.1880; p = 0.005)) and higher social vulnerability (overall SVI (I = 0.0599; p = 0.033)). CFR was associated with higher social vulnerability (SVI human capital (I = 0.0858; p = 0.004) and SVI urban infrastructure (I = 0.0985; p = 0.040)). Of the analysed cases, 55.4% were female; 2/3 were Black or Brown and the median age was 41 years. Among deaths, most were male (919; 57.4%) and elderly (1171; 73.1%). The predictors of death were male sex, advanced age and the presence of comorbidities. In Alagoas, Brazil, the disease has undergone a process of interiorisation and caused more deaths in poorer municipalities. The presence of comorbidities and advanced age were predictors of death.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 95%

COVID-19 in Brazil: spatial risk, social vulnerability, human development, clinical manifestations and predictors of mortality – a retrospective study with data from 59 695 individuals

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The pooled overall, prevalence of in-hospital death in Iran country is 12.16% (95% CI: 10.72%-13.61%). This estimation is upper than large cohort study that reported in-hospital death due to COVID-19 in China [8,9] and lower than study reported in in-hospital mortality in USA [11][12][13], Brazil [14], Spain [15][16][17], France [18,19] and Italy [20]. This prevalance is also lower than pooled meta prevalence of in-hospital mortality in patients with COVID-19 in the world [21].…”

Section: Discussionmentioning

confidence: 69%

“…COVID-19 patients had a very high ranging in-hospital death rate of admitted patients. The large cohort study in China ((9.6%)[8], 3.98% [9]), USA (8.2% [10], 18.58% [11], 45.11% [12], 22.77% [13]), Brazil (26.82% [14], Spain (21.3% [15], 20.90%[16], 21.41% [17]), France (16.87% [18], 27.72% [19]), Italy (28% [20]) reported various prevalence of in-hospital death due to COVID-19. Abate et al in a meta analysis study showed that the pooled prevalence of inhospital mortality in patients with coronavirus disease was 15% (95% CI: 13 to 17) [21].…”

Section: Contextmentioning

confidence: 99%

In-Hospital Death Due to COVID-19 Disease in Iranian Patients: A Systematic Review and Meta-Analysis Study

Ghanei

Saadat

Najimi-Varzaneh

et al. 2021

Preprint

View full text Add to dashboard Cite

Context: The prevalence of in-hospital death due to COVID-19 hospital is one of the qualitative indexes, which can be used to assess the quality of care, as well as the mortality patterns in COVID-19 pandemic.Objectives: Therefore, this systematic and meta-analysis study has been done with the aim of estimating overall prevalence in-hospital death due to COVID-19 disease in iranian patients Evidence Acquisition: Articles were identified through international searching databases including PubMed, Scopus, Elsevier, Google Scholar, and Web of Science and Iranian scientific information database (SID), Health.barakatkns, IranDoc, Civilica and MagIran. We reviewed systematically all studies reporting the prevalence of in-hospital death due to COVID-19 disease. In this study meta-analysis method with random effect model has been used to estimate the pooled prevalence. Results: 118 records were identified by the electronic search, of which 43 studies were identified as relevant papers that were meta-analyzed for the pooled in-hospital death due to COVID-19 prevalence. Overall, prevalence of death were 12.16% (95% CI: 10.72%-13.61%). The highest and lowest death prevalence has been reported in Northern Provinces (Gilan, 27.27% (95% CI: 8.66%-45.88%) and Mazandaran, 21.27% (95% CI: 18.14%-24.40%)) and Turkish-speaking provinces (Azerbaijan, East, 3.29% (95% CI: 2.11%-4.47%) and Zanjan, 3.42% (95% CI: 1.82%-5.02%)) respectively. Conclusions: Considering the death rate obtained in this study and its comparison with other countries, it can be said that the performance of the Iranian medical system in COVID-19 pandemic is acceptable.

show abstract

“…This result correlates with previous studies. Cardiovascular disease, cerebrovascular disease, chronic kidney disease and chron-ic lung disease were the most reported comorbidities (3,12,13).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Clinical Characteristics and Prognostic Laboratory Findings of COVID-19 Patients by Age Groups

Kutsoylu

Zeka

Omeroglu-Simsek

et al. 2021

Infect Dis Clin Microbiol

View full text Add to dashboard Cite

Objective: In this study, we determined the symptoms of the COVID-19 and defined agespecific symptoms that can help diagnose the disease on hospital admission. Materials and Methods:Patients who visited a university hospital's adult pandemia outpatient clinic with suspected COVID-19 symptoms and tested with SARS-CoV-2 polymerase chain reaction test between March 17 -May 17, 2020, were included in the study. Demographic data, symptoms on admission, prognostic laboratory tests and hospitalization were recorded.Results: Out of 5289 admissions, 639 (12.1%) patients had suspected or confirmed COVID-19. Patients were sorted incident to age groups to determine the difference in demographic data, comorbidities, symptoms, prognostic laboratory findings and outcome. The exposure history was lower in the 65-79 age group, contrary to the ≥ 80 age group. Sore throat, loss of smell and taste, headache and myalgia were specific to the 18-49 age group (p<0.001). Shortness of breath was represented 2.31 and 2.79 times higher in the 65-79 and the ≥ 80 age group, respectively, than the 18-49 age group. Comorbid diseases, prognostic laboratory tests (lymphopenia, C-reactive protein (CRP), D-dimer, ferritin) and hospitalization were found significantly higher in the ≥ 65 age group than the 18-49 age group. Conclusion:This study identifies the varieties in comorbidities, symptoms, prognostic laboratory findings and outcomes between the age-grouped patients referred to the outpatient clinic with suspected or confirmed COVID-19. We found that comorbidities, poor prognostic factors and hospitalization are more common in patients over 65 years. Shortness of breath is the most common symptom seen in the ≥ 65 age group compared to the 18-49 age group, where sore throat, loss of taste and smell are the symptoms commonly seen. Predominant symptoms for age groups help physicians differentiate the disease in clinical practice.

show abstract

Correlation between hospitalized patients’ demographics, symptoms, comorbidities, and COVID-19 pandemic in Bahia, Brazil

Cited by 23 publications

References 21 publications

COVID-19 in Brazil: spatial risk, social vulnerability, human development, clinical manifestations and predictors of mortality – a retrospective study with data from 59 695 individuals

COVID-19 in Brazil: spatial risk, social vulnerability, human development, clinical manifestations and predictors of mortality – a retrospective study with data from 59 695 individuals

In-Hospital Death Due to COVID-19 Disease in Iranian Patients: A Systematic Review and Meta-Analysis Study

Comparison of Clinical Characteristics and Prognostic Laboratory Findings of COVID-19 Patients by Age Groups

Contact Info

Product

Resources

About